Novo Nordisk said on 31 July 2026 that its ZEUS phase 3 trial of ziltivekimab did not cut major adverse cardiovascular events versus placebo, a setback for a drug meant to lower cardiovascular inflammation. The company said the once-monthly 15 mg treatment hit its biological targets, but that did not translate into fewer heart attacks, strokes or cardiovascular deaths.
The market is looking at Nvo stock because ZEUS was the clearest test yet of whether blocking the IL-6 pathway could turn lab changes into real-world protection in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. Novo Nordisk enrolled more than 6,300 people whose hsCRP levels were at least 2 mg/L, making this one of the company’s biggest late-stage bets in cardiovascular medicine.
The result was almost exact on paper and still negative in practice. The hazard ratio for MACE was 0.99, with a 95% confidence interval of 0.88 to 1.11. That means the trial’s outcome sat right on the line between benefit and no benefit, and the interval crossed 1.0, so there was no clear statistical signal that ziltivekimab reduced events. Martin Holst Lange said the expected biological effect did not result in MACE benefits in this population.
That is the friction point investors and clinicians will focus on. Ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, and Novo Nordisk has said the drug also lowered inflammation markers such as hsCRP. But lower inflammation markers did not add up to fewer major cardiovascular events, which is the standard that mattered in ZEUS. Overall rates of adverse events and serious adverse events were similar between the treatment groups, although a higher proportion of people on ziltivekimab had serious infections.
ZEUS is a double-blind, placebo-controlled cardiovascular outcomes study, and the readout matters because ziltivekimab has been positioned for cardiovascular disease, acute myocardial infarction and heart failure with preserved ejection fraction. Novo Nordisk said the outcome will not affect its previously communicated adjusted operating profit outlook for 2026, though it will lead to a non-cash impairment charge in Q3 2026.
The next checkpoint is already lined up. Full ZEUS results will be presented at an upcoming scientific meeting in 2026, and the HERMES and ARTEMIS trials are expected to continue with readouts in the first half of 2027. For now, the message from Bagsværd is simple: the biology moved, the event curve did not, and the key question is whether the company can still turn its inflammation strategy into a cardiovascular win elsewhere.
